scholarly journals PROSTATIC HYPERPLASIA;

2017 ◽  
Vol 24 (10) ◽  
pp. 1560-1565
Author(s):  
Muhammad Sheraz Javed ◽  
Safdar Hassan Javed
Keyword(s):  
Prostatic Hyperplasia ◽  
Significant Response ◽  
Age Group ◽  
Urinary Tract Symptoms ◽  
Prostate Size ◽  
Group A ◽  
Male Patients ◽  
Comparative Results ◽  
Group B ◽  
Lower Urinary

Lower Urinary Tract Symptoms. Alpha-1 adrenoceptor antagonists are mostfrequently prescribed medical management for LUTS and among these tamsulosin andterazosin are the most common. Objectives: To access comparison of efficacy of tamsulosinand terazosin for management of LUTS due to prostatic hyperplasia in terms of InternationalProstate Symptom Score (IPSS). Place and duration: Study being conducted at Departmentof Urology and Kidney Transplantation, Allied Hospital, Faisalabad for period of 24 months from01-07-2014 to 30-06-2016. Methodology: 659 male patients enrolled in study and randomlyassigned to Group A (Patients being administered with tamsulosin) and Group B (Patients beingadministered with terazosin) and improvement in IPSS monitored over period of two weeks.Results: 659 patients enrolled with mean age+sd as 61.9+10.2 years. Group A includes 330patients while Group B include 329 patients. Among Group A, 250 patients showed significantimprovement in IPSS while in Group B, 215 patients showed significant response to medicalmanagement in terms of IPSS and both groups showed statistically comparative response.Statistical response of management also determined in terms of variables of IPSS severity,prostatic size and age of patient and found that efficacy of the two groups were statisticallycomparable for patients with mild IPSS while in patients with moderate IPSS has response totreatment with tamsulosin but no statistical association of efficacy for treatment with terazosin.No statistical response was found for improvement in symptoms in cases with severe IPSS ineither groups. When response monitored in terms of prostate size in both groups, it was foundthat both groups have statistical response when prostate size is less than 35 grams, between35-55 grams but in case when prostate size was more than 55 grams, no statistical responsewas found with group B patients. When response was measured in terms of variable of age,results were consistent with the fact that statistically significant response of efficacy was foundin either groups for age group 45-55 years and 56-65 years but no statistical response wasfound for Group B when considered for age group more than 65 years. Conclusion: Based onresults it is concluded that both tamsulosin and terazosin has got comparative results in overallresponse. However, tamsulosin has superiority in treatment when IPSS is moderate, prostatesize is more than 55 grams and age of patient is more than 65 years.

scholarly journals Continuous versus Intermittent Tamsulosin Therapy in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized Control Trial

2020 ◽  
Vol 15 (1) ◽  
pp. 22-26
Author(s):  
SM Shameem Waheed ◽  
Mohammad Abdur Rakib ◽  
Md Shahidul Islam ◽  
Mohammad Abdur Rakib ◽  
Md Ashif Chowdhury ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Lower Urinary

Introduction: Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. About 50% of men at the age of 50 years develop BPH and about half of them report to the doctors with some form of lower urinary tract symptoms (LUTS). Objectives: To see the therapeutic effect of Tamsulosin on alternate day administration in comparison to daily dose for men who had been suffering from LUTS due to BPH. Materials and Methods: This clinical trial was carried out at Combined Military Hospital, Dhaka in a consecutive fashion for about 18 months. A total of 152 patients were selected from outpatient department and after assessing them through inclusion and exclusion criteria and grouped randomly in three groups Group-A (50 patients), Group-B (50 patients) and Group C (52 patients); all the patients were treated with Tablet Tamsulosin (0.4mg) daily for first three months. Then next 15 months they were treated as; Group-A received Tablet Tamsulosin (0.4mg) daily, Group-B received Tablet Tamsulosin (0.4mg) every alternate day and Group C received placebo Tablet (Folic acid 5 mg) daily. Data were collected at the beginning and end of 3rd month, 4th month, 7th month and 18th month of study, in the form of international prostate symptom score (IPSS), maximum urinary flow per second (Qmax) and post-voidal residue (PVR). Results: This study showed that at the initial three month, IPSS score declined in all three groups, Qmax improved and PVR reduced in all groups. In next phase of study; in Group-A patient there was progressive and significant improvement of all parameters (IPSS, Qmax and PVR) at the end of study. In Group-B patient also showed similar result at the end of study. In Group-C patient showed statistically significant difference in outcome in relation to Group-A and Group-B i.e. more in IPSS, less in Qmax and increase in PVR. Conclusion: With this study it is clearly evident that tamsulosin (0.4mg) therapy significantly improves symptoms of men suffering for LUTS due to BPH. And alternate day therapy having similar therapeutic outcome in relation to every day therapy. Journal of Armed Forces Medical College Bangladesh Vol.15 (1) 2019: 22-26

Efficacy of Alpha Blockers in Relieving Symptoms of JJ Stent

2021 ◽  
pp. 1-5
Author(s):  
Hassan Mansoor ◽  
◽  
Kashif Bangash Bangash ◽  
Syed Muhammad Kamran Majeed ◽  
Hassan Mumtaz ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Postoperative Period ◽  
Lower Urinary Tract ◽  
Control Group ◽  
Alpha Blockers ◽  
Urinary Tract Symptoms ◽  
Group A ◽  
Group B ◽  
Lower Urinary

Introduction: JJ stenting has been routinely used in endourology with a wide variety of implications. These stents have beneficial effects in postoperative period improving surgical outcome. Though they are widely used in urology practice, JJ stents cause lower urinary tract symptoms (LUTS) in majority of patients. The objective of this study was to test the hypothesis that alpha blockers reduce lower urinary tract symptoms (LUTS) after rigid ureterorenoscopy in postoperative time period up to 3 weeks. Study Design: It was a randomized clinical trial (RCT). Setting: The study was conducted in KRL hospital, Islamabad. Patients presenting in outpatient / emergency department were selected for the study. Duration of Study: Six months (15th July 2016 to 15th Jan’ 2017) Methods: A prospective randomized study was conducted in total 100 patients undergoing rigid ureterorenoscopy (URS). Patients were randomized into an intervention Group A and Control Group B. In Group A tamsulosin 0.4mg was given after rigid ureterorenoscopy, while in Group B no tamsulosin was given except placebo. Primary outcome were lower urinary tract symptoms (LUTS), which were measured by international prostate symptoms score (IPSS) up to 3 weeks postoperatively. Results: The mean IPSS at 3rd week in postoperative phase of rigid URS for Group A was 4.76± 4.14315 and in Group B was 27.28 ± 5.03879 with the P value of 0.0001 which was statistically significant and also less than 0.05. So IPSS was statistically lower in Group A as compared to Group B up to 3 weeks post operatively. In conclusion, a significant statistical difference was found for Double J (DJ) stent related symptoms between the two groups. Conclusion: Alpha blockers reduce lower urinary tract symptoms (LUTS) in postoperative period of rigid ureterorenoscopy up to 3 weeks.

scholarly journals Eswl for Upper Ureteric Stone With and Without JJ Stent-A Comparative Study

2020 ◽  
Vol 17 (1) ◽  
pp. 17-22
Author(s):  
Promode Ranjan Singh ◽  
Md Abdul Alim ◽  
Md Shafiqul Islam ◽  
Kaiser Ahmed ◽  
Jalal Ahmed Choudhury
Keyword(s):  
Lower Urinary Tract ◽  
Single Session ◽  
Ureteric Stone ◽  
Urinary Tract Symptoms ◽  
Group A ◽  
Ureteric Colic ◽  
Group B ◽  
Jj Stent ◽  
Stented Group ◽  
Lower Urinary

Objective: To find out the outcome of stenting before ESWL in the management of upper ureteric stone. Methods and materials: This prospective comparative study was conducted in the department of urology, Sylhet Osmani Medical College Hospital from January 2011 to June 2012. Sixty two patients with upper ureteric stone, aged between 18 to 60 years irrespective of sex, unilateral radio opaque upper ureteric stone of greatest diameter 2cm, patients with normal renal function and negative urine culture and were agreed to participate in the study were selected. Selected 62 patients with upper ureteric stones were divided randomly into group-A and group-B each consisting 31 patients. The patients of group-A were treated with ESWL with a JJ stent and that of group-B without JJ stent. In the patients selected for JJ placement, a 5 fr JJ stent was placed under regional anaesthesia before ESWL. Siemens Lithotripsy ESWL machine was used to impart shock waves and 3500 shockwaves was given in a session. Both the groups were compared for stone clearance, ureteric colic, steinstrasse, fever, lower urinary tract symptoms (LUTS), number of ESWL sessions. Data were processed and analyzed using software SPSS. Results: The number ESWL session in stented group [single session 10 (32.3%) and multiple sessions 21 (67.7%)] and in non-stented group [single session 9 (29.0%) and multiple sessions 22 (71.0%)] was similar in both groups (p>0.05) Stones were cleared in 23 (74.2%) patients in stented group and 25 (80.6%) patients in non-stented group. Difference was not statistically significant (p>0.05). Ureteric colic was significantly fewer in stented group than that of non-stented group [4 (12.9%) vs 11 (35.5%); p<0.05] but surapubic pain was significantly more in stented group than that of non-stented group [13 (41.9%) vs 5 (16.1%); p<0.05]; while steinstrasse [3 (9.7%) vs 5 (16.1%); p>0.05] and fever [5 (16.1%) vs 2 (6.5%); p>0.05] did not differ statistically significant between groups. Lower urinary tract symptoms such as urinary frequency [15 (48.4%) vs 3 (9.7%); p<0.01]; urgency [17 (54.8%) vs 5 (16.1%); p<0.01] and dysuria [19 (61.3%) vs 6 (19.4%); p<0.01] were significantly more in stented group than that of non-stented group; but gross haematuria [21 (67.7%) vs 15 (48.4%); p>0.05] were more in stented group. Conclusion: ESWL is an effective and reasonable initial therapy in the management of upper ureteric stones measuring <2 cm. Pre-ESWL ureteric stenting provides no additional benefit over non-stented ESWL in their management. Moreover, stents are associated with signiûcant patient discomfort and morbidity. Bangladesh Journal of Urology, Vol. 16, No. 1, Jan 2014 p.17-22

Sign in / Sign up

Export Citation Format

Share Document